| LEGN ALERT: Levi & Korsinsky Investigates Legend Biotech Corporation for Possible Securities Fraud Violations |
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Legend Biotech Corporation ("Legend Biotech Corporation") (NASDAQ:LEGN) concerning possible violations of federal securities laws. On May 13, 2024, Legend published first quarter financial results and business updates, including, among other things, news that the Company is navigating regulatory challenges, such as the need for FDA approval for the expansion of its Raritan manufacturing facility. |
accessnewswire.com |
2025-05-15 19:45:00 |
Czytaj oryginał (ang.) |
| Legend Biotech Corporation (LEGN) Q1 2025 Earnings Call Transcript |
Legend Biotech Corporation (NASDAQ:LEGN ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Caroline Paul - Associate Director, IR Ying Huang - Chief Executive Officer Jessie Yeung - Interim Chief Financial Officer Mythili Koneru - Chief Medical Officer Guowei Fang - President, R&D Alan Bash - President, CARVYKTI Conference Call Participants Gena Wang - Barclays Jessica Fye - JPMorgan Yaron Werber - TD Cowen Kostas Biliouris - BMO Capital Jonathan Miller - Evercore ISI Leonid Timashev - RBC James Shin - Deutsche Bank Mitchell Kapoor - H.C. Wainright Jeet Mukherjee - BTIG Ashwani Verma - UBS Sean McCutcheon - Raymond James Operator Good day, and thank you for standing by. |
seekingalpha.com |
2025-05-13 15:15:39 |
Czytaj oryginał (ang.) |
| Legend Biotech Reports First Quarter 2025 Results and Recent Highlights |
SOMERSET, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its first quarter 2025 unaudited financial results and key corporate highlights. |
globenewswire.com |
2025-05-13 11:00:00 |
Czytaj oryginał (ang.) |
| What Makes Legend Biotech (LEGN) a New Buy Stock |
Legend Biotech (LEGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-05-02 17:05:33 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Legend Biotech (LEGN) Could Surge 135.16%: Read This Before Placing a Bet |
The consensus price target hints at a 135.2% upside potential for Legend Biotech (LEGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2025-05-02 15:01:03 |
Czytaj oryginał (ang.) |
| Legend Biotech (LEGN) Moves 5.1% Higher: Will This Strength Last? |
Legend Biotech (LEGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road. |
zacks.com |
2025-04-16 14:55:44 |
Czytaj oryginał (ang.) |
| Cell Therapy Maker Legend Biotech Is An 'Attractive Opportunity' Due To No Material Tariff Exposure: Analyst |
With U.S. President Donald Trump's tariffs, HC Wainwright analyst writes that investors are looking for companies with macroeconomic moats that protect against tariff exposure and regulatory uncertainty. |
benzinga.com |
2025-04-08 18:59:30 |
Czytaj oryginał (ang.) |
| Legend Biotech Corporation (LEGN) Q4 2024 Earnings Call Transcript |
Legend Biotech Corporation (NASDAQ:LEGN ) Q4 2024 Earnings Conference Call March 11, 2025 8:00 AM ET Company Participants Caroline Paul - Associate Director, IR Ying Huang - CEO Jessie Yeung - Interim CFO Mythili Koneru - Chief Medical Officer Guowei Fang - President, R&D Alan Bash - President, CARVYKTI Conference Call Participants Jon Miller - Evercore Hang Hu - Barclays Yaron Werber - TD Cowen Jessica Fye - JPMorgan Ziyi Chen - Goldman Sachs Leonid Timashev - RBC Capital Markets Vikram Purohit - Morgan Stanley Kostas Biliouris - BMO Capital Mitchell Kapoor - H.C. Wainright James Shin - DB Jeet Mukherjee - BTIG Ash Verma - UBS George Farmer - Scotiabank Sean McCutcheon - Raymond James Rick Bienkowski - Cantor Fitzgerald Prem Lachman - Maximus Capital Operator Good day, and welcome to the Legend Biotech Fourth Quarter and Full-Year 2024 Earnings Call. |
seekingalpha.com |
2025-03-11 14:06:47 |
Czytaj oryginał (ang.) |
| Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights |
SOMERSET, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported financial results for the fourth quarter and year ended December 31, 2024, and key corporate highlights. |
globenewswire.com |
2025-03-11 09:00:00 |
Czytaj oryginał (ang.) |
| Top 5 Commercial Biotech Buyout Candidates: Legend Biotech (No. 4) |
Legend Biotech is a commercial-stage biotech company specializing in innovative cell therapies, with a strong pipeline and global R&D presence. LEGN's flagship product, CARVYKTI, has received multiple regulatory approvals and shows significant sales growth, with potential peak sales of at least $3B. The company has an impressive pipeline (with 11 non-CARVYKTI related programs), high growth rates, and strong liquidity stance with $1.2B in cash, ensuring funding into 2026, and low dilution risk. |
seekingalpha.com |
2025-01-07 17:40:54 |
Czytaj oryginał (ang.) |
| Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
SOMERSET, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company's Chief Executive Officer, will present the latest company updates at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Tuesday, January 14, 2025, at 3:45 p.m. PT. |
globenewswire.com |
2024-12-19 10:01:00 |
Czytaj oryginał (ang.) |
| CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma |
SOMERSET, N.J., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today new results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) provided significantly higher rates of minimal residual disease (MRD)-negativity in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD, compared to standard therapies of pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd).1 MRD negativity is a prognostic marker of prolonged survival outcomes for patients with multiple myeloma.1 These results reinforce the clinical value of CARVYKTI® as early as second line and support the recent achievement of overall survival (OS) benefit versus standard therapies1. The MRD negativity findings were featured as an oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract #1032) in San Diego, California.1 |
globenewswire.com |
2024-12-09 21:35:00 |
Czytaj oryginał (ang.) |
| Legend Biotech: The Story Brightens |
Legend Biotech's Carvykti, a CAR-T therapy, has shown significant sales growth since being launched in 2022. The company has some $1.2 billion in cash on its balance sheet and losses are projected to fall dramatically in coming years as revenues soar. Analyst firms are quite optimistic on Legend, with nine analyst firms issuing Buy ratings since Q3 numbers were released with price targets between $73-$94 a share. |
seekingalpha.com |
2024-12-05 16:14:42 |
Czytaj oryginał (ang.) |
| Legend Biotech Corporation (LEGN) Q3 2024 Earnings Call Transcript |
Legend Biotech Corporation (NASDAQ:LEGN ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Jessie Yeung - Vice President of Investor Relations and Finance Ying Huang - Chief Executive Officer Lori Macomber - Chief Financial Officer Mythili Koneru - Chief Medical Officer Steve Gavel - Senior Vice President, Commercial Development, U.S. & Europe Conference Call Participants Gena Wang - Barclays Kelly Shi - Jefferies Jessica Fye - JPMorgan Kostas Biliouris - BMO Capital James Shin - DB Vikram Purohit - Morgan Stanley Mitchell Kapoor - H.C. Wainright Rick Bienkowski - Cantor Fitzgerald Sean McCutcheon - Raymond James Operator Ladies and gentlemen, thank you for standing by. |
seekingalpha.com |
2024-11-12 16:45:07 |
Czytaj oryginał (ang.) |
| Legend Biotech (LEGN) Reports Q3 Earnings: What Key Metrics Have to Say |
Although the revenue and EPS for Legend Biotech (LEGN) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2024-11-12 12:31:17 |
Czytaj oryginał (ang.) |
| Legend Biotech (LEGN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now |
After losing some value lately, a hammer chart pattern has been formed for Legend Biotech (LEGN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term. |
zacks.com |
2024-11-11 12:55:12 |
Czytaj oryginał (ang.) |
| Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition |
SOMERSET, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a live webcast event for investors on Sunday, December 8, 2024, at 8:00 p.m. PT (11:00 p.m. ET) during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA. |
globenewswire.com |
2024-11-07 09:30:00 |
Czytaj oryginał (ang.) |
| Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma |
New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of CARVYKTI to transform outcomes in refractory multiple myeloma |
globenewswire.com |
2024-11-05 11:10:00 |
Czytaj oryginał (ang.) |
| Legend Biotech Appoints Alan Bash as President of CARVYKTI® |
Newly created position to lead efforts focused on continued growth and sales Newly created position to lead efforts focused on continued growth and sales |
globenewswire.com |
2024-11-04 09:30:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe Legend Biotech (LEGN) Could Rally 90.83%: Here's is How to Trade |
The mean of analysts' price targets for Legend Biotech (LEGN) points to a 90.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2024-10-24 14:55:21 |
Czytaj oryginał (ang.) |
| Stock Picks From Seeking Alpha's September 2024 New Analysts |
In September, thirty new analysts joined Seeking Alpha, offering diverse stock picks and insights, from Strong Buy to Strong Sell ratings. Highlighted picks include InMode Ltd., Intel Corporation, and iShares 20+ Year Treasury Bond ETF, each with unique investment theses and strong buy ratings. Analysts' backgrounds range from software engineering to finance, enhancing their stock research with diverse perspectives and methodologies. |
seekingalpha.com |
2024-10-04 12:00:00 |
Czytaj oryginał (ang.) |
| Legend Biotech to set up new R&D facility in Philadelphia |
Legend Biotech said on Thursday it would set up a new research and development facility in Philadelphia, Pennsylvania, to advance its portfolio of next-generation cell therapies. |
reuters.com |
2024-10-03 11:41:52 |
Czytaj oryginał (ang.) |
| Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia |
New 31,000 square-foot facility will enhance Legend's leading cell therapy portfolio and expand Legend's R&D capabilities as a global cell therapy leader New 31,000 square-foot facility will enhance Legend's leading cell therapy portfolio and expand Legend's R&D capabilities as a global cell therapy leader |
globenewswire.com |
2024-10-03 11:30:00 |
Czytaj oryginał (ang.) |
| Johnson & Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients |
Friday, Legend Biotech Corporation LEGN and Johnson & Johnson JNJ announced late-breaking three-year follow-up data from the Phase 3 CARTITUDE-4 study. |
benzinga.com |
2024-09-30 13:47:37 |
Czytaj oryginał (ang.) |
| CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line |
SOMERSET, N.J., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced late-breaking three-year follow-up data from the Phase 3 CARTITUDE-4 study that shows a single infusion of CARVYKTI® (ciltacabtagene autoleucel) significantly extended overall survival (OS) in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor (PI), and an immunomodulatory agent (IMiD), reducing the risk of death by 45 percent versus standard therapies of pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd).1 CARVYKTI® is now the first and only cell therapy to improve OS versus standard therapies for patients with lenalidomide-refractory multiple myeloma as early as second line.1 These results were presented as a late-breaking oral presentation at the 2024 International Myeloma Society (IMS) Annual Meeting (Abstract #OA-65) in Rio de Janeiro, Brazil.1 |
globenewswire.com |
2024-09-27 20:35:00 |
Czytaj oryginał (ang.) |
| Legend Biotech: Entering Accelerated Growth Phase, Carvykti Positions Company For Valuation Expansion |
Carvykti, a CAR-T therapy co-developed by Legend Biotech & J&J, is central to second-line multiple myeloma treatment. Both firms are actively scaling up production across bases. Carvykti sales surged 60% YoY, reaching US$343 million in 1H2024, forecasting US$1 bilion+ for the full year. Rumors since July claim Legend Biotech faced a takeover bid, with fresh whispers of pricing disputes in negotiations this week. |
seekingalpha.com |
2024-09-18 10:39:23 |
Czytaj oryginał (ang.) |
| Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference |
SOMERSET, N.J., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company's Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY on Wednesday, September 4, 2024, at 2:35 p.m. ET. |
globenewswire.com |
2024-08-20 12:00:00 |
Czytaj oryginał (ang.) |
| Legend Biotech Corporation (LEGN) Q2 2024 Earnings Call Transcript |
Legend Biotech Corporation (NASDAQ:LEGN ) Q2 2024 Earnings Call Transcript August 9, 2024 8:00 AM ET Company Participants Jessie Yeung - VP of IR & Finance Ying Huang - CEO Lori Macomber - CFO Steve Gavel - Head of Commercial Development for US and Europe Guowei Fang - CSO Conference Call Participants Gena Wang - Barclays Jessica Fye - JPMorgan Kelly Shi - Jefferies Ash Verma - UBS Leonid Timashev - RBC Capital Markets Jonathan Miller - Evercore ISI Yaron Werber - TD Cowen James Shin - Deutsche Bank Vikram Purohit - Morgan Stanley Justin Zelin - BTIG Mitchell Kapoor - H.C. Wainwright George Farmer - Scotiabank Rick Bienkowski - Cantor Fitzgerald Sean McCutcheon - Raymond James Asthika Goonewardene - Truist Operator Ladies and gentlemen, thank you for standing by. |
seekingalpha.com |
2024-08-09 20:25:22 |
Czytaj oryginał (ang.) |
| Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights |
SOMERSET, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its second quarter 2024 unaudited financial results and key corporate highlights. |
globenewswire.com |
2024-08-09 11:00:00 |
Czytaj oryginał (ang.) |
| Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024 |
SOMERSET, N.J., July 26, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced preliminary, unaudited financial results for the six-months ended June 30, 2024. |
globenewswire.com |
2024-07-26 11:00:00 |
Czytaj oryginał (ang.) |